AtheroGenics Announces Five Abstracts Accepted for the American Diabetes Association's 68th Annual Scientific Sessions
04 June 2008 - 9:30PM
Marketwired
ATLANTA, GA , a pharmaceutical company focused on the treatment
of chronic inflammatory diseases, announced today that five
abstracts, which describe both clinical and pre-clinical diabetes
and cardiovascular data from studies of its novel drug candidate,
AGI-1067, have been accepted for the American Diabetes
Association's (ADA) 68th Scientific Sessions taking place at the
Moscone Convention Center in San Francisco, Calif. from June 6-10,
2008.
A "Late Breaking Clinical Studies" oral presentation entitled,
"Delay in Progression to Type 2 Diabetes in Patients with
Cardiovascular Disease Treated with a Novel Anti-Inflammatory,
Anti-Oxidant, AGI-1067: Evidence from ARISE," is scheduled for
Monday, June 9, at 5:00 p.m. PT by Jean-Claude Tardif, M.D.,
Director of Research, Professor of Medicine, Montreal Heart
Institute, University of Montreal.
The ADA's Annual Scientific Sessions is the nation's largest
meeting for endocrinologists and other health care professionals
involved in diabetes research and the delivery of diabetes
care.
Other AtheroGenics abstracts include:
-- "AGI-1067 Improves Glycemic Control When Added to Current Regimens in
Patients with Type 2 Diabetes." This poster, 443-P, will be presented by
Eric Klug, M.D., Sunninghill Hospital, Sunninghill, Gauteng, South Africa,
and will be displayed from Saturday, June 7, through Monday, June 9, 2008
in the Poster Hall.
-- "Effects of AGI-1067 on Cardiovascular (CV) Risk in Patients with Type
2 Diabetes or Impaired Fasting Glucose (IFG) in the ARISE Trial." This
abstract, 2065-PO, by lead author John J. McMurray, M.D., Professor of
Medical Cardiology, University of Glasgow, and Honorary Consultant
Cardiologist, Western Infirmary, Glasgow, Scotland, was accepted for
publication in the ADA Scientific Sessions Abstract Book.
-- "AGI-1067, a Novel Antioxidant and Anti-Inflammatory Agent, Improves
Insulin Sensitivity in a Rat Model of Diet-Induced Obesity," Cynthia L.
Sundell, Ph.D., Vice President of Pharmacology, AtheroGenics. This poster,
345-P, will be displayed from Saturday, June 7 through Monday, June 9, 2008
in the Poster Hall.
-- "AGI-1067, a Novel Antioxidant and Anti-Inflammatory Agent, Inhibits
Activation of JNK, IRS-1 Serine Phosphorylation and Cytokine Production in
Adipocytes," Xilin Chen, Ph.D., Senior Principal Scientist, AtheroGenics.
This poster, 1262-P, will be displayed from Saturday, June 7 through
Monday, June 9, 2008 in the Poster Hall.
About AGI-1067
AGI-1067 is a novel oral drug candidate with demonstrated
anti-inflammatory and antioxidant properties. AGI-1067 works by
selectively inhibiting signaling pathways that are activated in
response to oxidative stress and pro-inflammatory stimuli.
Oxidative stress and inflammation have been implicated as playing a
key role in the pathogenesis of insulin resistance and
diabetes.
AtheroGenics recently announced interim results of ANDES, a
double-blind, placebo controlled study for the treatment of Type 2
diabetes. ANDES is evaluating two dose levels of AGI-1067 given
once daily over six months. The primary efficacy endpoint is change
in hemoglobin A1c (A1c) from baseline compared to placebo in
patients with Type 2 diabetes. The interim analysis of 806 patients
who completed three months in the study showed dose-related,
statistically significant reductions in A1c. Final results of the
trial are expected in the third quarter 2008.
About AtheroGenics
AtheroGenics is focused on the discovery, development and
commercialization of novel drugs for the treatment of chronic
inflammatory diseases, including diabetes and coronary heart
disease (atherosclerosis). The Company's lead antioxidant and
anti-inflammatory drug candidate, AGI-1067, is being studied in a
Phase III clinical trial known as ANDES (AGI-1067 as a Novel
Anti-Diabetic Agent Evaluation Study), for the treatment of
diabetes. In addition, the Company has other clinical and
preclinical anti-inflammatory compounds, including AGI-1096, an
oral agent for the prevention of organ transplant rejection. For
more information about AtheroGenics, please visit
http://www.atherogenics.com.
CONTACTS: AtheroGenics, Inc. Mark P. Colonnese Executive Vice
President 678-336-2511 Email Contact Media Inquiries Jayme Maniatis
/ Dana Conti Schwartz Communications, Inc. 781-684-0770 Email
Contact Investor Inquiries Lilian Stern Stern Investor Relations,
Inc. 212-362-1200 Email Contact
KraneShares Artificial I... (NASDAQ:AGIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
KraneShares Artificial I... (NASDAQ:AGIX)
Historical Stock Chart
From Sep 2023 to Sep 2024